Last reviewed · How we verify
S-1 single
S-1 is an oral combination chemotherapy agent that inhibits thymidylate synthase and other folate metabolism enzymes to disrupt DNA synthesis in cancer cells.
S-1 is an oral combination chemotherapy agent that inhibits thymidylate synthase and other folate metabolism enzymes to disrupt DNA synthesis in cancer cells. Used for Gastric cancer, Colorectal cancer, Pancreatic cancer.
At a glance
| Generic name | S-1 single |
|---|---|
| Also known as | S-1 |
| Sponsor | Sun Yat-sen University |
| Drug class | Oral fluoropyrimidine combination |
| Target | Thymidylate synthase, dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
S-1 combines tegafur (a prodrug of 5-fluorouracil), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase), and oteracil potassium (an inhibitor of orotate phosphoribosyltransferase). This triple combination enhances 5-FU bioavailability and reduces gastrointestinal toxicity by modulating fluoropyrimidine metabolism, leading to prolonged anti-tumor effects.
Approved indications
- Gastric cancer
- Colorectal cancer
- Pancreatic cancer
Common side effects
- Nausea and vomiting
- Diarrhea
- Anorexia
- Bone marrow suppression (leukopenia, thrombocytopenia)
- Hand-foot syndrome
- Stomatitis
Key clinical trials
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
- A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma (PHASE2)
- Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer (PHASE2)
- First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics (PHASE1)
- Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial (PHASE2)
- Causal Role of Rostromedial Prefrontal Cortex for Positive Savoring in Depression (NA)
- Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease (NA)
- Effectiveness of Transcranial Magnetic Stimulation (TMS) in Smoking Cessation, Combining Withdrawal Stimulation Followed by Maintenance Stimulation to Prevent Relapse (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S-1 single CI brief — competitive landscape report
- S-1 single updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI